RESUMEN
Preclinical data support the activity of celecoxib and fluvastatin in high-grade (HGG) and low-grade gliomas (LGG). A phase I trial (NCT02115074) was designed to evaluate the safety of this combination in children with refractory/relapsed HGG and LGG using four dose levels of fluvastatin with a fixed daily dose of celecoxib. A Continual Reassessment Method was used for fluvastatin dose escalation. Dose-limiting toxicities (DLT) were determined on the first treatment cycle. Twenty patients were included. Ten LGG and ten HGG patients received a median of 3.5 treatment cycles. Two DLTs were reported: one grade 3 maculopapular rash (4 mg/kg dose level) and one grade 4 increase of Creatine Phospho-Kinase (6 mg/kg dose level). We identified the dose of 6 mg/kg/day as the recommended phase II dose (RP2D) of fluvastatin with celecoxib. Four patients with LGG continued treatment beyond 12 cycles because of stable disease, including one patient who received 23 treatment cycles. In children with refractory/relapsed glioma, the RP2D of fluvastatin with celecoxib is 6 mg/kg/day. The long-term stable diseases observed in LGG suggest a possible role of the combination in a maintenance setting, given its good tolerance and low cost for children living in low- and middle-income countries.
RESUMEN
Dental care, which has long been neglected by health policies, is now an integral part of a multi-professional health system. The nurse, an essential sentinel in hospital structures, plays a key role in the patient's dental care. At the dawn of an increasingly personalized medicine, initiatives are being implemented to decompartmentalize the skills of each specialty.
Asunto(s)
Rol de la Enfermera , Salud Bucal , Política de Salud , HumanosRESUMEN
The increasing high-volume demand for polymer matrix composites (PMCs) brings into focus the need for autoclave alternative processing. Trapped rubber processing (TRP) of PMCs is a method capable of achieving high pressures during polymer matrix composite processing by utilizing thermally induced volume change of a nearly incompressible material inside a closed cavity mold. Recent advances in rubber materials and computational technology have made this processing technique more attractive. Elastomers can be doped with nanoparticles to increase thermal conductivity and this can be further tailored for local variations in thermal conductivity for TRP. In addition, recent advances in computer processing allow for simulation of coupled thermomechanical processes for full part modeling. This study presents a method of experimentally characterizing prospective rubber materials. The experiments are designed to characterize the dynamic in situ change in temperature, the dynamic change in volume, and the resulting real-time change in surface pressure. The material characterization is specifically designed to minimize the number and difficulty of experimental tests while fully capturing the rubber behavior for the TRP scenario. The experimental characterization was developed to provide the necessary data for accurate thermomechanical material models of nearly incompressible elastomeric polymers for use in TRP virtual design and optimization.
RESUMEN
BACKGROUND: DEPOSEIN (NCT01645839) was a randomized open-label phase III study to explore the role of intrathecal chemotherapy in patients with newly diagnosed leptomeningeal metastasis (LM), a common manifestation of breast cancer. METHODS: Patients with newly diagnosed LM defined by tumor cells in the cerebrospinal fluid or combination of clinical and neuroimaging signs of LM were randomized to receive systemic therapy alone (control group) or systemic therapy plus intrathecal liposomal cytarabine (experimental group). Progression-free survival related to LM (LM-PFS) was the primary endpoint. RESULTS: Thirty-seven and 36 patients were assigned to the control and the experimental groups. Median number of liposomal cytarabine injections in the experimental group was 5 (range 1-20). Focal radiotherapy was performed in 6 (16%) and 3 (8%) patients in the control and experimental groups. In the intent-to-treat population, median LM-PFS was 2.2 months (95% CI: 1.3-3.1) in the control versus 3.8 months (95% CI: 2.3-6.8) in the experimental group (hazard ratio 0.61, 95% CI: 0.38-0.98) (P = 0.04). Seventy-one patients have died. Median overall survival was 4.0 months (95% CI: 2.2-6.3) in the control versus 7.3 months (95% CI: 3.9-9.6) in the experimental group (hazard ratio 0.85, 95% CI: 0.53-1.36) (P = 0.51). Serious adverse events were reported in 22 and 30 patients, respectively. Quality of life until progression did not differ between groups. CONCLUSION: The addition of intrathecal liposomal cytarabine to systemic treatment improves LM-related PFS. Confirmatory trials with optimized patient selection criteria and more active drugs may be required to demonstrate a survival benefit from intrathecal pharmacotherapy.
Asunto(s)
Neoplasias de la Mama , Carcinomatosis Meníngea , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Citarabina , Humanos , Inyecciones Espinales , Calidad de VidaRESUMEN
French program of breast cancer screening is implemented since15 years and results are in adequation with international guidelines except for participation. To answer to recurrent controversies about breast cancer screening, publications from National Institute of French cancer registry confirm the positive impact of screening on decreasing mortality for participating women. The harms of mammography (and not from screening) need to be communicated to the invited women to help them to make decision about participation but also the risk of worse prognosis in case of symptomatic cancer. The future of screening will be different and works are in progress to find new ways to select women who will beneficiate for screening and whose cancer needs to be treated. Until then, the only way to screen for breast cancer stays the mammographic process as well as other technics in case of dense breast or in case of family history of breast cancer.
Asunto(s)
Actitud del Personal de Salud , Neoplasias de la Mama/prevención & control , Detección Precoz del Cáncer , Mamografía , Radiólogos/psicología , Adulto , Anciano , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/epidemiología , Toma de Decisiones , Disentimientos y Disputas , Detección Precoz del Cáncer/psicología , Detección Precoz del Cáncer/estadística & datos numéricos , Femenino , Francia/epidemiología , Humanos , Imagen por Resonancia Magnética , Mamografía/efectos adversos , Mamografía/métodos , Mamografía/psicología , Mamografía/estadística & datos numéricos , Metaanálisis como Asunto , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto , Utilización de Procedimientos y Técnicas , Exposición a la Radiación , Ultrasonografía MamariaRESUMEN
BACKGROUND: A scorecard to evaluate magnetic resonance imaging (MRI) findings during the course of leptomeningeal metastases (LM) has been proposed by the Response Assessment in Neuro-Oncology (RANO) group. METHODS: To explore the feasibility of the Leptomeningeal Assessment in Neuro-Oncology (LANO) scorecard, cerebrospinal MRIs of 22 patients with LM from solid tumors were scored by 10 neuro-oncologists and 9 neuroradiologists at baseline and at follow-up after treatment. Raters were blinded for clinical data including treatment. Agreement between raters of single items was evaluated using a Krippendorff alpha coefficient. Agreement between numerical parameters such as scores for changes between baseline and follow-up and total scores was evaluated by determining the intraclass coefficient of correlation. RESULTS: Most raters experienced problems with the instructions of the scorecard. No acceptable alpha concordance coefficient was obtained for the rating of single items at baseline or follow-up. The most concordant ratings were obtained for spinal nodules. The concordances were worst for brain linear leptomeningeal enhancement and cranial nerve enhancement. Discordance was less prominent among neuroradiologists than among neuro-oncologists. High variability was also observed for evaluating changes between baseline and follow-up and for total scores. CONCLUSIONS: Assessing response of LM by MRI remains challenging. Central imaging review is therefore indispensable for clinical trials. Based on the present results, we propose a new, simplified scorecard that will require validation using a similar approach as pursued here. The main challenges are to define measurable versus nonmeasurable (target) lesions and measures of change that allow assessment of response.
Asunto(s)
Ensayos Clínicos como Asunto/normas , Imagen por Resonancia Magnética/métodos , Neoplasias Meníngeas/secundario , Neoplasias/patología , Neuroimagen/métodos , Evaluación del Resultado de la Atención al Paciente , Adulto , Anciano , Terapia Combinada , Progresión de la Enfermedad , Estudios de Factibilidad , Femenino , Estudios de Seguimiento , Humanos , Masculino , Neoplasias Meníngeas/líquido cefalorraquídeo , Neoplasias Meníngeas/terapia , Persona de Mediana Edad , Neoplasias/líquido cefalorraquídeo , Neoplasias/terapia , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
Therapeutic options of leptomeningeal metastases include intra-cerebrospinal fluid (CSF) chemotherapy. Among intra-CSF agents, liposomal cytarabine has advantages but can induce specific toxicities. A BRAF-V600E-mutated melanoma leptomeningeal metastases patient, treated by dabrafenib and liposomal cytarabine, presented after the first injection of liposomal cytarabine with hyperthermia and headaches. Despite sterile CSF/blood analyses, extended intravenous antibiotics were given and the second injection was delayed. The diagnosis of chemical meningitis was finally made. Dose reduction and appropriate symptomatic treatment permitted the administration of 15 injections of liposomal cytarabine combined with dabrafenib. A confirmation of the diagnosis of chemical meningitis is essential in order (1) not to delay intra-CSF or systemic chemotherapy or (2) to limit the administration of unnecessary but potentially toxic antibiotics.
Asunto(s)
Antimetabolitos Antineoplásicos/efectos adversos , Citarabina/efectos adversos , Carcinomatosis Meníngea/tratamiento farmacológico , Meningitis/inducido químicamente , Antimetabolitos Antineoplásicos/administración & dosificación , Citarabina/administración & dosificación , Humanos , Inyecciones Espinales , Masculino , Melanoma/tratamiento farmacológico , Melanoma/secundario , Persona de Mediana Edad , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/secundario , Melanoma Cutáneo MalignoRESUMEN
Ventricular access devices (VAD) offer several advantages compared to intralumbar injections for the administration of intra-CSF agents in the treatment of leptomeningeal metastases (LM). However, there are few prospective studies reporting on complications with the use of VADs. All complications were prospectively collected that pertained to the implantation and use of a VAD in consecutive patients with solid tumor-related LM from June 2006 to December 2013. Clinical follow-up was every 2 weeks during the initial 2 months of treatment and then once monthly. Complete neuraxis MRI was performed at baseline and then every 2-3 months. A total of 112 patients (88 women) with a mean age of 51.1 years (range 26-73) were included. Primary cancers included breast (79 patients), lung (12) and melanoma (6). All patients were treated with intra-CSF liposomal cytarabine. 72 % of the patients received concomitant systemic and intra-CSF chemotherapy. The placement of the VAD was performed under local anesthesia in all cases. The mean operative time was 15 min and no perioperative complications were reported. The mean number of intraventricular injections per patient was 9.34 (range 1-47). A total of 11 complications in 11 patients were seen including 7 infections, 1 intracranial hemorrhage, 2 instances of symptomatic leukoencephalopathy and 1 catheter malpositioning. 8 complications required an operation and 1 complication was fatal. The use of a VAD is safe and may improve patients' comfort and compliance with LM-directed therapy.
Asunto(s)
Catéteres de Permanencia/efectos adversos , Inyecciones Intraventriculares/efectos adversos , Inyecciones Intraventriculares/instrumentación , Neoplasias Meníngeas/tratamiento farmacológico , Neoplasias Meníngeas/secundario , Adulto , Anciano , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/efectos adversos , Encéfalo/patología , Neoplasias de la Mama/patología , Citarabina/administración & dosificación , Citarabina/efectos adversos , Femenino , Estudios de Seguimiento , Humanos , Neoplasias Pulmonares/patología , Imagen por Resonancia Magnética , Masculino , Melanoma/patología , Neoplasias Meníngeas/patología , Neoplasias Meníngeas/cirugía , Persona de Mediana Edad , Estudios Prospectivos , Médula Espinal/patologíaRESUMEN
OBJECTIVE: The Response Evaluation Criteria in Solid Tumors (RECIST) can have limitations when used to evaluate local treatments for cancer, especially for liver malignancies treated by stereotactic body radiation therapy (SBRT). The aim of this study was to validate the relationship between the occurrence of lobulated enhancement (LE) and local relapse and to evaluate the utility of this relationship for predicting local progression. PATIENTS AND METHODS: Imaging data of 59 lesions in 46 patients, including 281 computed tomographic (CT) scans, were retrospectively and blindly reviewed by 3 radiologists. One radiologist measured the lesion size, for each CT and overall, to classify responses using RECIST threshold criteria. The second studied LE occurrence. A third radiologist was later included and studied LE occurrence to evaluate the interobserver consistency for LE evaluation. RESULTS: The mean duration of follow-up was 13.6 months. LE was observed in 16 of 18 progressive lesions, occurring before size-based progression in 50% of cases, and the median delay of LE detection was 3.2 months. The sensitivity of LE to predict progression was 89%, and its specificity was 100%. The positive predictive value was 100%, the negative predictive value was 95.3%, and the overall accuracy was 97%. The probability of local progression-free survival at 12 months was significantly higher for lesions without LE compared with all lesions: 0.80 (CI 95%: 0.65-0.89) versus 0.69 (CI 95%: 0.54-0.80), respectively. The overall concordance rate between the 2 readers of LE was 97.9%. CONCLUSION: Response assessment of liver metastases treated by SBRT can be improved by including LE. This study demonstrates the diagnostic and predictive utility of LE for assessing local progression at a size still eligible for local salvage treatment.
Asunto(s)
Neoplasias Hepáticas/cirugía , Radiocirugia/métodos , Adulto , Anciano , Anciano de 80 o más Años , Distribución de Chi-Cuadrado , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/secundario , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Variaciones Dependientes del Observador , Estudios Retrospectivos , Terapia Recuperativa , Sensibilidad y Especificidad , Estadísticas no Paramétricas , Tomografía Computarizada por Rayos X , Adulto JovenRESUMEN
BACKGROUND: Survival of patients with leptomeningeal metastases (LM) and impaired functional status is limited to several months, and rarely does neurological function improve with treatment. CASE REPORT: A 34-year-old female with hormone-negative and HER2-positive metastatic breast cancer was diagnosed with bulky radiographic LM 45 months after initial diagnosis. She was treated with intra-CSF trastuzumab followed by intra-CSF liposomal cytarabine; however, the cancer progressed 8 months after the diagnosis of LM. At the time of the third LM progression, the patient presented with a cauda equina syndrome and cerebellar impairment resulting in an inability to walk. She was treated with CNS-directed radiotherapy (lumbosacral and cerebellar) and bevacizumab plus vinorelbine. Rapid functional improvement occurred, and the patient regained the ability to walk and independently manage her daily activities. Twelve months later, she presented with rapid progression of the LM resulting in death within several weeks. CONCLUSION: In radiographically defined bulky LM, the combination of systemic therapy and CNS-directed radiotherapy likely is more active than intra-CSF therapy only. In lieu of the rapid and significant improvement in neurological function combined with the prolonged response, bevacizumab alone or in combination with chemotherapy and CNS-directed radiotherapy may be considered in select patients with radiographically bulky breast cancer-related LM.
RESUMEN
Thymic epithelial tumors are rare and often occur somewhere local. Metastatic sites of thymic carcinomas (Masaoka-Koga stage IVb) are mostly seen in the lung, liver and brain. We report a 64-year-old female with an initial diagnosis of thymoma B3 who first showed thoracic recurrences and then an asymptomatic isolated pelvic metastasis from her thymic carcinoma.
RESUMEN
PURPOSE: To report experience with fiducial marker insertion and describe an advantageous, novel technique for fiducial placement in the liver for stereotactic body radiation therapy with respiratory tracking. METHODS AND MATERIALS: We implanted 1444 fiducials (single: 834; linked: 610) in 328 patients with 424 hepatic lesions. Two methods of implantation were compared: the standard method (631 single fiducials) performed on 153 patients from May 2007 to May 2010, and the cube method (813 fiducials: 610 linked/203 single) applied to 175 patients from April 2010 to March 2013. The standard method involved implanting a single marker at a time. The novel technique entailed implanting 2 pairs of linked markers when possible in a way to occupy the perpendicular edges of a cube containing the tumor inside. RESULTS: Mean duration of the cube method was shorter than the standard method (46 vs 61 minutes; P<.0001). Median numbers of skin and subcapsular entries were significantly smaller with the cube method (2 vs 4, P<.0001, and 2 vs 4, P<.0001, respectively). The rate of overall complications (total, major, and minor) was significantly lower in the cube method group compared with the standard method group (5.7% vs 13.7%; P=.013). Major complications occurred while using single markers only. The success rate was 98.9% for the cube method and 99.3% for the standard method. CONCLUSIONS: We propose a new technique of hepatic fiducial implantation that makes use of linked fiducials and involves fewer skin entries and shorter time of implantation. The technique is less complication-prone and is migration-resistant.
Asunto(s)
Marcadores Fiduciales , Neoplasias Hepáticas/cirugía , Hígado , Movimiento , Radiocirugia/instrumentación , Respiración , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Femenino , Marcadores Fiduciales/efectos adversos , Migración de Cuerpo Extraño , Humanos , Masculino , Persona de Mediana Edad , Implantación de Prótesis/efectos adversos , Implantación de Prótesis/métodos , Radiocirugia/métodos , Radioterapia Guiada por Imagen/instrumentación , Factores de Tiempo , Adulto JovenRESUMEN
The incidence of leptomeningeal metastases is increasing, due to the improvement of the management and the overall survival of cancer patients. Although the diagnosis may be sometimes difficult to assess, an early treatment before the setting of neurological deficits is required in order to improve the quality of life of the patients. The median survival of untreated patients is 4 to 6 weeks. Specific treatment may prolong survival by several months. The treatment requires a combination of chemotherapy and targeted therapies administrated systemically or via intra-cerebrospinal fluid route, surgery and radiotherapy. Patient management is specific but requires a multidisciplinary approach, which may vary according to the characteristics of meningeal disease, the characteristics of primary tumors, the general condition of patients and previous lines of treatments.
Asunto(s)
Neoplasias Meníngeas/secundario , Neoplasias/patología , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Continuidad de la Atención al Paciente , Irradiación Craneana/métodos , Diagnóstico por Imagen/métodos , Humanos , Neoplasias Meníngeas/diagnóstico , Neoplasias Meníngeas/terapia , Neoplasias/diagnóstico , Neurocirugia/métodos , PronósticoRESUMEN
BACKGROUND/AIM: Prolonged overall survival (OS) has been reported for selected patients with leptomeningeal metastases (LM). The management and treatment of such patients is poorly-described. We report our experience on breast cancer (BC)-associated LM and patients with prolonged survival. PATIENTS AND METHODS: Eleven patients with BC and LM had an OS >12 months in which treatment is described. RESULTS: Combined intra-cerebro spinal fluid (CSF) and systemic treatment were administered until disease progression or toxicity in all but two patients. Involved-field radiotherapy was administered to two patients. Median OS in this selected cohort following LM diagnosis, was 21.0 (range=13-33.3) months. CONCLUSION: Prolonged OS but also prolonged responses can be observed in BC with LM. An individualized and multi-disciplinary approach is advised for the management of these patients.